Zoetis Inc. $ZTS Shares Acquired by Clifford Swan Investment Counsel LLC

Posted by on Sep 1st, 2026

Clifford Swan Investment Counsel LLC increased its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 27.8% in the second quarter, Holdings Channel reports. The firm owned 189,326 shares of the company’s stock after purchasing an additional 41,175 shares during the quarter. Clifford Swan Investment Counsel LLC’s holdings in Zoetis were worth $13,605,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Kerrisdale Advisers LLC bought a new position in Zoetis during the 2nd quarter worth approximately $3,018,000. Headlands Technologies LLC bought a new stake in shares of Zoetis in the 2nd quarter valued at approximately $3,960,000. Quantitative Investment Management LLC acquired a new stake in shares of Zoetis during the 2nd quarter valued at approximately $3,242,000. Moore Capital Management LP acquired a new stake in shares of Zoetis during the second quarter worth $14,570,000. Finally, Sigma Planning Corp lifted its holdings in Zoetis by 32.7% in the second quarter. Sigma Planning Corp now owns 12,694 shares of the company’s stock worth $912,000 after acquiring an additional 3,131 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.5%

Shares of ZTS stock opened at $76.99 on Tuesday. The company has a market cap of $31.81 billion, a PE ratio of 12.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $156.49. The business’s 50 day moving average is $75.59 and its two-hundred day moving average is $95.04.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the prior year, the company earned $1.76 earnings per share. The business’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, August 7th. BNP Paribas Exane dropped their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday, August 7th. Finally, Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research note on Tuesday, August 25th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $107.43.

Check Out Our Latest Research Report on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.